Genomics in breast cancer - Therapeutic implications

Nature Clinical Practice Oncology

Volumn 2, Issue 1, 2005, Pages 26-33

  Lønning, Per Eystein ^a   Sørlie, Therese ^b   Børresen Dale, Anne Lise ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b Kreftforeningen   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Expression profiling; Prediction; Prognosis; Therapy response

Indexed keywords

ANTHRACYCLINE; DOCETAXEL;

BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER RESEARCH; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; DNA MICROARRAY; DRUG SENSITIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; HUMAN; IN VIVO STUDY; ONCOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT CARE PLANNING; PROGNOSIS;

EID: 16244371172     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0072     Document Type: Review

References (47)

1. Levi F et al. (2001) The fall in breast cancer mortality in Europe. Eur J Cancer 37: 1409-1412
2. Abe O et al. (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942
3. Early Breast Cancer Trialist Group (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351: 1451-1467
4. Citron ML et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439
5. Lønning PE (2003) Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 4: 177-185
6. Muss HB et al. (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early Breast cancer. N Engl J Med 330: 1260-1266
7. Aas T et al. (1996) Specif ic P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814
8. Holloway AJ et al. (2002) Options available-from start to finish-for obtaining data from DNA microarrays. Nat Genet 32: 481-489
9. Quackenbush J (2001) Computational analysis of microarray data. Nat Rev Genet 2: 418-427
10. Ball CA et al. (2002) Standards for Microarray data. Science 298: 539
11. Perou CM et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
12. Sorlie T et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874
13. Sorlie T et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423
14. Sotiriou C et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398
15. Zhao HJ et al. (2004) Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15: 2523-2536
16. Geisler S et al. (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512
17. van't Veer LJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
18. Ma XJ et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616
19. Beer D et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824
20. Glinsky GV et al. (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913-923
21. Pomeroy SL et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442
22. Chung CH et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500
23. Shipp MA et al. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74
24. Nakamura T et al. (2004) Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23: 2385-2400
25. Weiss MM et al. (2003) Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene 22: 1872-1879
26. Bertucci F et al. (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23: 1377-1391
27. Yeoh E et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143
28. Rosenwald A et al. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198: 851-862
29. van de Vijver MJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
30. Ahr A et al. (2002) Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359: 131-132
31. Onda M et al. (2004) Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancer. J Cancer Res Clin Oncol 130: 537-545
32. Huang E et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet 361: 1590-1596
33. Nagahata T et al. (2004) Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. Cancer Sci 95: 218-225
34. Huang E et al. (2003) Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog Horm Res 58: 55-73
35. Pittman J et al. (2004) Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A 101: 8431-8436
36. Eden P et al. (2004) "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40: 1837-1841
37. Ein-Dor L et al. (2004) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics [doi: 10.1093/bioinformatics/bth469]
38. Chang J et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369
39. Ayers M et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293
40. Brenton JD and Caldas C (2003) Predictive cancer genomics-what do we need? Lancet 362: 340-341
41. Ellis M and Ballman K (2004) Trawling for genes that predict response to breast cancer adjuvant therapy. J Clin Oncol 22: 2267-2269
42. Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
43. Kannan K et al. (2001) DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20: 2225-2234
44. Yoon H et al. (2002) Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A 99: 15632-15637
45. Muller A et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50
46. Vousden KH and Lu X (2002) Live or let die: The cell's response to p53. Nat Rev Cancer 2: 594-604
47. Lønning PE (2004) Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance. Trends Mol Med 10: 113-118